Adverse left ventricular remodeling by glycoprotein nonmetastatic melanoma protein B in myocardial infarction
Anne Järve1,2, Silke Mühlstedt1,3,4, Fatimunnisa Qadri1
1Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Abstract:
Cardiac diseases are the leading cause of death. Available treatment approaches are not sufficient to reverse persistent cardiac damage after injury; thus, the search for new therapeutic targets is essential. Our microarray-based screening in rat hearts 24 h after myocardial infarction (MI) yielded glycoprotein nonmetastatic melanoma protein B (GPNMB), which is known to be involved in inflammation and fibrosis after tissue injury. However, its role in the heart was elusive. We found increased cardiac expression levels of GPNMB in rats and mice after MI. Analysis of DBA/2J mice, which lack functional GPNMB due to a spontaneous point mutation, showed that systemic GPNMB deficiency was associated with preserved cardiac function and less left ventricular dilation after MI compared with DBA/2J mice with reconstituted GPNMB expression. These improvements were associated with decreased expression of matrix metalloproteinase 9, the cardiac stress genes for natriuretic peptides (atrial natriuretic peptide and brain natriuretic peptide), and β-myosin heavy chain after MI. Moreover, GPNMB deficiency attenuated the dilated cardiomyopathy in muscle lim protein knockout mice but could not prevent cardiac hypertrophy induced by isoprenaline infusion. This is the first experimental study to show that GPNMB adversely influences myocardial remodeling.-Järve, A., Mühlstedt, S., Qadri, F., Nickl, B., Schulz, H., Hübner, N., Özcelik, C., Bader, M. Adverse left ventricular remodeling by glycoprotein nonmetastatic melanoma protein B in myocardial infarction.
Insights
Glycoprotein nonmetastatic melanoma protein B (GPNMB) worsens heart damage after myocardial infarction. Reducing GPNMB levels protected cardiac function and reduced adverse remodeling in mouse models, highlighting GPNMB as a potential therapeutic target.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pathology
Background:
- Cardiac diseases are a leading cause of mortality globally.
- Current treatments for myocardial infarction (MI) cannot fully reverse cardiac damage.
- Identifying novel therapeutic targets for cardiac injury is crucial.
Purpose of the Study:
- To investigate the role of glycoprotein nonmetastatic melanoma protein B (GPNMB) in cardiac remodeling after myocardial infarction (MI).
- To determine if GPNMB influences cardiac function and adverse structural changes post-MI.
Main Methods:
- Microarray screening identified GPNMB in rat hearts post-MI.
- Cardiac GPNMB expression was analyzed in rat and mouse models of MI.
- GPNMB deficiency effects were studied in DBA/2J mice and muscle lim protein knockout mice.
Main Results:
- Cardiac GPNMB expression increased after MI in rodents.
- GPNMB deficiency preserved cardiac function and reduced left ventricular dilation post-MI.
- GPNMB deficiency decreased matrix metalloproteinase 9 and cardiac stress gene expression.
Conclusions:
- GPNMB plays an adverse role in myocardial remodeling following ischemic injury.
- Targeting GPNMB may offer a novel therapeutic strategy for mitigating cardiac damage after MI.
- GPNMB deficiency attenuated dilated cardiomyopathy but not pressure-overload hypertrophy.
More Related Videos
09:29An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
